Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2021 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abl8282
Abstract: Remdesivir (RDV) is a nucleotide analog prodrug with demonstrated clinical benefit in patients with coronavirus disease 2019 (COVID-19). In October 2020, the U.S. FDA approved intravenous RDV as the first treatment for hospitalized COVID-19 patients.… read more here.
Keywords: sars cov; inhalation; inhaled remdesivir; remdesivir ... See more keywords